Therefore, cladribine and alemtuzumab substantially impair immune defenses against infection.
Some studies have indicated that omitting a second dose of
alemtuzumab may still result in effective disease control. However, additional
data are required to determine whether this omission affects the
long-term efficacy of the therapy.